Merck Sharp & Dohme France (MSD France)
This sponsor has funded 2 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 5333 | Finalised | Annual investigate of EMEND prescription | No | No |
| 13721 | Finalised | Observational study to quantify in real life the contribution of SINGULAIR ® 4mg in children aged from 6 to 24 months (NA) | No | No |
PAS by Risk Management Plan (RMP) requirement
Merck Sharp & Dohme France (MSD France)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Merck Sharp & Dohme France (MSD France)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Merck Sharp & Dohme France (MSD France)
1 Study countries specified are the following:
- France